LENALIDOMIDE (Revlimid) prior authorization at UnitedHealthcare
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
UnitedHealthcare requires Thalidomide Analog prior-authorization documentation for LENALIDOMIDE (Revlimid): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
UnitedHealthcare reviews LENALIDOMIDE (Revlimid) prior authorizations against its medical policy for Thalidomide Analog. UnitedHealthcare-specific context: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Thalidomide Analog
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- UnitedHealthcare's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- GLP-1 weight-loss exclusion
- Out-of-network reduction citing UCR
- Step therapy on biologics
- Prior auth denied for advanced imaging
- Quantity limits on specialty drugs
LENALIDOMIDE (Revlimid)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- REMS program requirement
- Specialty pharmacy restriction
- Quantity limit
Brand: Revlimid. REMS-restricted distribution.
Manufacturer patient-assistance program: Revlimid PSP — relevant when a UnitedHealthcare denial sticks and the patient needs bridge access while appealing.
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.uhcprovider.com) with the same packet plus an applicable, current clinical source supporting LENALIDOMIDE (Revlimid)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a UnitedHealthcare denial on DenialHelp.
Contact UnitedHealthcare
- Provider portal: https://www.uhcprovider.com
Frequently asked questions
What documentation does UnitedHealthcare need for LENALIDOMIDE (Revlimid) prior auth?
UnitedHealthcare's typical PA packet for LENALIDOMIDE (Revlimid): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Thalidomide Analog, expect clinical-criteria documentation specific to this class.
What's the turnaround time at UnitedHealthcare?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for LENALIDOMIDE (Revlimid) at UnitedHealthcare?
Preparation scenarios to check against the current notice and policy include: GLP-1 weight-loss exclusion; Out-of-network reduction citing UCR; Step therapy on biologics. These are not measured frequency claims. For LENALIDOMIDE (Revlimid), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
How do I prep for a peer-to-peer with UnitedHealthcare on LENALIDOMIDE (Revlimid)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the LENALIDOMIDE (Revlimid) PA packet
Open ApprovalHelp — generate a LENALIDOMIDE (Revlimid) prior-auth packet tailored to UnitedHealthcare's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com